AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05125861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
Study NCT05125861 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
Study NCT00079937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
Study NCT00079937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
Study NCT00079937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
Study NCT00079937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
Study NCT02582203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline
Study NCT02582203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT01106287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
Study NCT01106287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: a single oral placebo will be administered in the designated period (Periods 1-5)
Study NCT03685747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin one-time 20 mg/kg intraperitoneal dose.
Study NCT00868205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Description: 3 or 5 cups of coffee daily for eight weeks
Study NCT03597308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg of Oxycodone every 6 hours as needed for pain
Description: 5mg of Oxycodone every 6 hours as needed for pain
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: intraoperative
Study NCT04106817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, wild-type A/California/H1N1 2009 influenza virus
Description: Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
Study NCT03023137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking & dietary modification
Description: 1. Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention
Study NCT04409379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Relative telomere length
Description: Relative telomere length in peripheral blood cell
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: continuous postoperatively
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: continuous postoperatively
Study NCT00017238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN5500
Description: Given IV
Study NCT00017238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00892918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
Description: Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
Study NCT03384693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03332771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT02642874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Description: Methocarbamol twice daily
Study NCT02642874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate twice daily
Study NCT03597308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 600mg of Ibuprofen every 6 hours as needed for pain
Description: 600mg of Ibuprofen every 6 hours as needed for pain
Study NCT03597308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500mg of Acetaminophen every 6 hours as needed for pain
Description: 500mg of Acetaminophen every 6 hours as needed for pain
Study NCT04476043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Oral; Tablet
Study NCT04476043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; Tablet
Study NCT01174550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Description: Use of standard equipment for usual-care testing
Study NCT01174550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Echocardiogram
Description: Use of standard equipment for usual-care testing
Study NCT01174550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nuclear Stress Test
Description: Use of standard equipment for usual-care testing
Study NCT01174550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Electrocardiogram
Description: Use of standard equipment for usual-care testing
Study NCT03082300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: Oral
Study NCT02821312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-8010
Description: Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010.
Study NCT02821312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010.
Study NCT01618331 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular exercise
Description: Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
Study NCT01618331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular exercise
Description: Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
Study NCT01618331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein-carbohydrate supplementation
Description: Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
Study NCT00730418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Treatment with doxazosin 4mg daily for 24 mos
Study NCT00730418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Treatment with doxazosin 8mg daily for 24 mos
Study NCT01293461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX129801
Description: Subcutaneous injection
Study NCT01293461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT03880656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of autologous BM-MNCs
Description: Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
Study NCT00984178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Granulocite Colony Stimulating Factor treatment (G-CSF)
Description: G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
Study NCT00984178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells
Description: Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
Study NCT00797862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
Study NCT00797862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
Study NCT00797862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
Study NCT02087033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ritmonutra
Description: 2 tablets a day by mouth for 4 weeks
Study NCT02087033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
Study NCT06395363 — intervention group
Intervention type: PROCEDURE
Intervention: fixation method
Description: The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
Study NCT00049114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00049114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00049114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00049114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00049114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo complete resection
Study NCT00049114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04109482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-102
Description: The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered.
Study NCT04109482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min).
Study NCT04109482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
Study NCT04359056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy activities along the care pathways
Description: PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses.~Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs.~Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge~* Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary~* Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary~* Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected.
Study NCT01789203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
Study NCT01789203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
Study NCT02538640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-SDS biscuit
Description: Consumption of the high-SDS product (50g) alone with a glass of water
Study NCT02538640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-SDS extruded cereals
Description: Consumption of the low-SDS product (42g) alone with a glass of water
Study NCT03666429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulb suction
Description: Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
Study NCT02743312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torso Weights
Description: Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
Study NCT03666429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoseFrida
Description: Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
Study NCT04694560 — intervention group
Intervention type: OTHER
Intervention: Treatment Free Observation
Description: Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
Study NCT03350321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Study NCT03350321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
Study NCT02883504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echo-Doppler examination and left heart catheterization
Study NCT00354029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S (+) Ketamine
Description: 0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
Study NCT00354029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study NCT01387256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical abortion
Description: pregnancy termination with drugs
Study NCT01387256 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: medical abortion
Description: pregnancy termination with drugs
Study NCT04463082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous administration of fluids
Description: Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
Study NCT00723294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Study NCT00723294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT03487666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
Study NCT03487666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
Study NCT03487666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
Study NCT03554187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic periodontal Debridement, with appropriate device
Description: Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.